BioSyent Inc.'s Share Buyback Program Announcement
BioSyent Inc. is thrilled to share that the TSX Venture Exchange has approved its Notice of Intention to undertake a Normal Course Issuer Bid (NCIB). This initiative will empower the company to buy back up to 690,000 of its common shares over the next year. As of mid-December, these shares represent around 6.07% of the total shares currently outstanding.
Details of the Normal Course Issuer Bid
The NCIB is set to begin soon, allowing BioSyent to strategically repurchase shares at the market price. The purchases will be executed on the TSX Venture Exchange and other approved trading platforms, with a maximum limit of 227,393 shares every 30 days. This plan shows BioSyent's commitment to enhance shareholder value through diligent financial management.
Execution of Share Purchases
To facilitate these purchases, BioSyent has engaged Raymond James Ltd. to implement an automatic share purchase plan. This plan will permit the acquisition of shares during specified blackout periods, ensuring that BioSyent remains compliant while effectively managing its share repurchases. Outside of these periods, decisions on buying shares will be made by the company’s senior management team, emphasizing transparency and strategic planning.
Company Outlook and Shareholder Benefits
BioSyent is driven by the belief that its shares may occasionally trade at values that do not reflect the company's true potential in line with its innovative pursuits. By executing this buyback initiative, the company aims to optimize its capital allocation, ultimately benefiting existing shareholders. It believes that periodic share repurchases are a sound investment choice given the anticipated advantages for stakeholders.
Past Share Repurchases
In its proactive approach, BioSyent has successfully repurchased a total of 2,988,025 shares since late 2018, averaging $7.10 per share. Recently, from December 19, 2023, to December 13, 2024, the company bought back an additional 396,600 shares at an average price of $10.03. These figures highlight BioSyent’s ongoing commitment to returning capital to its shareholders while maintaining a solid financial position.
About BioSyent Inc.
BioSyent Inc. is a growth-oriented specialty pharmaceutical entity listed on the TSX Venture Exchange under the ticker symbol RX. The company focuses on acquiring and in-licensing innovative pharmaceutical products that have proven effective in improving patient wellbeing. It operates several business units dedicated to marketing, supporting healthcare professionals, and enhancing patient care.
Current Market Position
As of now, BioSyent has approximately 11,369,656 common shares outstanding, positioning itself strongly in the pharmaceutical landscape. The company remains dedicated to driving value and growth through its strategic initiatives and innovative approaches.
Frequently Asked Questions
What is the objective of BioSyent's NCIB?
The NCIB aims to allow BioSyent to repurchase shares while enhancing value for its existing shareholders, reflecting the company's commitment to responsible capital management.
How many shares can BioSyent repurchase under the NCIB?
BioSyent has approval to buy back up to 690,000 shares over the course of a year, which is about 6.07% of its outstanding shares.
Who is managing BioSyent's share purchases?
Raymond James Ltd. has been engaged to manage the share repurchase plan in conjunction with BioSyent’s senior management.
How does BioSyent perceive the current valuation of its shares?
BioSyent believes its shares may sometimes undervalue its activities and future growth prospects, motivating the need for a buyback program.
What has been BioSyent's history with share repurchases?
Since late 2018, BioSyent has repurchased nearly 2.99 million shares, reflecting its ongoing strategy to enhance shareholder equity and trust.
